Investigating how certain cell signaling affects insulin secretion in diabetes
Official title: Secretagogue and Gi/o-GPCR signaling through the islet Na+/K+-ATPase in health and diabetes
Funded at Vanderbilt University · NIH-11123304 · Data updated 2026-11-12
This study is looking at how certain signals in the pancreas affect insulin and somatostatin release, which is important for people with type-2 diabetes, to help find new ways to better manage blood sugar levels.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | August 24, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $505,744 |
| NIH project number | 5R01DK136768-03 |
| Project ID | NIH-11123304 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with type-2 diabetes who experience difficulties in blood glucose regulation.
✕Less likely to help
Patients without diabetes or those with other forms of diabetes may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms that regulate insulin and somatostatin secretion in the pancreas, particularly in patients with type-2 diabetes. It examines how specific receptors in the islet cells influence calcium handling and insulin release, which are critical for maintaining blood sugar levels. By studying both human and animal models, the research aims to uncover how disruptions in these signaling pathways contribute to diabetes. The findings could lead to new therapeutic strategies to improve glucose regulation in affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for managing blood sugar levels in patients with type-2 diabetes.
How similar studies have gone: Previous research has shown promising results in understanding similar signaling pathways in diabetes, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Jacobson, David Aaron — Vanderbilt University
- Study coordinator: Jacobson, David Aaron
Related research
Other NIH-funded projects on the same topics.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Retinal signals in early diabetes and how they affect vision
This grant looks at how diabetes changes the signals in the retina that control vision, with a focus on inner retinal cells and how these changes may lead to vision problems.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Bringing WHO HEARTS-D diabetes care into Bangladesh cities
A program to help urban clinics in Bangladesh adopt WHO HEARTS-D guidelines to improve detection, treatment, and control of type 2 diabetes.
-
AI-powered fundus imaging to screen for type 2 diabetes
A mobile AI tool uses eye images to help screen adults for type 2 diabetes in clinics or communities.
-
AI-powered eye imaging to screen for type 2 diabetes with a mobile phone
A plan to use AI on smartphone retinal images to help spot type 2 diabetes early, especially in people who may not have easy access to care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.